Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare antineutrophil cytoplasmic antibody-associated vasculitis that typically presents with asthma, eosinophilia and small-to-medium vessel ...
Feb. 7—(StatePoint) An estimated 5,000 people in the United States are living with Eosinophilic Granulomatosis with Polyangiitis (EGPA), a rare form of vasculitis that causes inflammation or swelling ...
Since GSK’s Nucala and AstraZeneca’s Fasenra were approved two years apart to treat patients with severe asthma, the IL-5 inhibitors have engaged in a spirited market battle, with one key difference: ...
The US Food and Drug Administration (FDA) has approved benralizumab (Fasenra) for the treatment of adults with eosinophilic granulomatosis with polyangiitis (EGPA), formerly known as Churg-Strauss ...
Rituximab did not show superiority over conventional therapy in inducing remission in patients with eosinophilic granulomatosis with polyangiitis (EGPA). Both treatment groups had similar remission ...
Eosinophilic granulomatosis with polyangiitis (EGPA) is a systemic inflammatory disease characterized by eosinophilia, an abnormal increase in eosinophils—a type of white blood cell—and inflammation ...
The agency has approved Nucala (mepolizumab) to treat Eosinophilic Granulomatosis with Polyangiitis (EGPA) to GlaxoSmithKline. This indication is the first FDA-approved therapy specifically to treat ...
Dublin, Jan. 28, 2026 (GLOBE NEWSWIRE) -- The "Eosinophilic Granulomatosis with Polyangiitis - Market Insight, Epidemiology, and Market Forecast - 2034" has been added to ResearchAndMarkets.com's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results